Journal of International Psychiatry

[Abstract] Objective To investigate the effect of risperidone combined with fluoxetine in the treatment of refractory schizophrenia negative symptoms and its effect on TESS and quality of life. Methods From January 2015 to October 2016, 172 patients with refractory schizophrenia were randomly divided into control group (n = 86) and experimental group (n = 86). The control group was treated with oral Fluoxetine treatment, the experimental group based on the control group plus risperidone treatment. Comparison of two groups of clinical efficacy, negative symptoms, quality of life and adverse reactions occurred. Results The total effective rate of the experimental group was higher than that of the control group (60.47% vs 38.37%). After 8 weeks of treatment, the PANSS scores of the two groups were decreased, and the experimental group was significantly lower. (P <0.05). There was no significant difference between the two groups (P> 0.05). There was no significant difference between the two groups (P> 0.05). The difference was statistically significant (P> 0.05). Conclusion Risperidone combined with fluoxetine in the treatment of refractory schizophrenia can significantly improve the clinical efficacy, improve the negative symptoms, while improving the quality of life without increasing the adverse reactions, worthy of clinical application.

[Key words] Fluoxetine;Risperidone;Refractory schizophrenia;Negative symptoms;TESS;Quality of Life